BioWorld

Sep. 30, 2009

View Archived Issues

Plexxikon Drug Quickly Moves From Phase I to Pivotal Trials

In relatively short order, Plexxikon Inc. has moved its melanoma product from a Phase I study to pivotal trials, the first of which has begun enrolling patients. (BioWorld Today) Read More

Dynavax: Phase III Heplisav Bid May Stretch to Europe, Canada

Read More

Repair Qualities of Macrophages, Hope for Muscle Regeneration

Read More

NewCo News: KemPharm: LATs Strengthen Safety of Available Therapies

Read More

'Dark' Days for Sequenom as Ax Falls on Top Executives

Read More

Other News To Note

Read More

Clinic Roundup

Read More

Financings Roundup

Read More